Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
MOMA Therapeutics
C Ray Therapeutics
National Cancer Institute (NCI)
Aragon Pharmaceuticals, Inc.
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Eli Lilly and Company
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
ARTBIO Inc.
Albert Einstein College of Medicine
Weill Medical College of Cornell University
Agenus Inc.
National Cancer Institute (NCI)
University of California, San Francisco
Atavistik Bio, Inc
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
University of Texas Southwestern Medical Center
University of Pennsylvania
Amgen
Memorial Sloan Kettering Cancer Center
Icahn School of Medicine at Mount Sinai
Eli Lilly and Company
NeoTX Therapeutics Ltd.
City of Hope Medical Center
Thomas Jefferson University
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Thomas Jefferson University
Icahn School of Medicine at Mount Sinai
City of Hope Medical Center
Jonsson Comprehensive Cancer Center
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
Columbia University
Dana-Farber Cancer Institute
Theratechnologies
Ohio State University Comprehensive Cancer Center
Turku University Hospital
Carisma Therapeutics Inc
NGM Biopharmaceuticals, Inc
National University Hospital, Singapore